Regulus Says USPTO Allows Claims in miRNA-Related Patent Application

The patent application, No. 20050261218 and titled "Oligomeric Compounds and Compositions for Use in Modulation [of] Small Non-Coding RNAs," claims methods of inhibiting the liver-specific miRNA miR-122, which has been shown to play a role in hepatitis C virus replication.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.